Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jeffrey Bennett to Multiple Sclerosis

This is a "connection" page, showing publications Jeffrey Bennett has written about Multiple Sclerosis.

 
Connection Strength
 
 
 
6.355
 
  1. Owens GP, Fellin TJ, Matschulat A, Salas V, Schaller KL, Given KS, Ritchie AM, Navarro A, Blauth K, Hughes EG, Macklin WB, Bennett JL. Pathogenic myelin-specific antibodies in multiple sclerosis target conformational proteolipid protein 1-anchored membrane domains. J Clin Invest. 2023 10 02; 133(19).
    View in: PubMed
    Score: 0.631
  2. Bennett JL. Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis: Sprinting to the Finish. Neurology. 2023 09 05; 101(10):420-421.
    View in: PubMed
    Score: 0.622
  3. Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, Galetta SL. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023 01; 22(1):89-100.
    View in: PubMed
    Score: 0.587
  4. Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics. 2021 01; 18(1):364-377.
    View in: PubMed
    Score: 0.518
  5. Liu Y, Given KS, Owens GP, Macklin WB, Bennett JL. Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. Glia. 2018 12; 66(12):2575-2588.
    View in: PubMed
    Score: 0.445
  6. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler. 2012 Sep; 18(9):1204-8.
    View in: PubMed
    Score: 0.288
  7. Bennett JL, Owens GP. Cerebrospinal fluid proteomics: a new window for understanding human demyelinating disorders? Ann Neurol. 2012 May; 71(5):587-8.
    View in: PubMed
    Score: 0.286
  8. Owens GP, Gilden D, Burgoon MP, Yu X, Bennett JL. Viruses and multiple sclerosis. Neuroscientist. 2011 Dec; 17(6):659-76.
    View in: PubMed
    Score: 0.278
  9. Gordon LK, Bennett JL. Preserving and restoring optic nerve function. J Neuroophthalmol. 2010 Dec; 30(4):303-4.
    View in: PubMed
    Score: 0.259
  10. Bennett JL, St?ve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol. 2009 May-Jun; 32(3):121-32.
    View in: PubMed
    Score: 0.232
  11. Owens GP, Winges KM, Ritchie AM, Edwards S, Burgoon MP, Lehnhoff L, Nielsen K, Corboy J, Gilden DH, Bennett JL. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol. 2007 Nov 01; 179(9):6343-51.
    View in: PubMed
    Score: 0.209
  12. Kaur P, Bennett JL. Optic neuritis and the neuro-ophthalmology of multiple sclerosis. Int Rev Neurobiol. 2007; 79:633-63.
    View in: PubMed
    Score: 0.198
  13. Simon JH, Zhang S, Laidlaw DH, Miller DE, Brown M, Corboy J, Bennett J. Identification of fibers at risk for degeneration by diffusion tractography in patients at high risk for MS after a clinically isolated syndrome. J Magn Reson Imaging. 2006 Nov; 24(5):983-8.
    View in: PubMed
    Score: 0.195
  14. Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res. 2006 Apr; 28(3):291-8.
    View in: PubMed
    Score: 0.187
  15. Samadzadeh S, Olesen MN, Wirenfeldt M, M?ller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N. Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects. Mult Scler. 2023 Dec; 29(14):1721-1735.
    View in: PubMed
    Score: 0.158
  16. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Paul F, Pittock SJ, Fujihara K, Palace J. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 03; 22(3):268-282.
    View in: PubMed
    Score: 0.150
  17. Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, Zuroff L, Bennett JL, von B?dingen HC, Carruthers R, Edwards KR, Fallis R, Giacomini PS, Greenberg BM, Hafler DA, Ionete C, Kaunzner UW, Lock CB, Longbrake EE, Pardo G, Piehl F, Weber MS, Ziemssen T, Jacobs D, Gelfand JM, Cross AH, Cameron B, Musch B, Winger RC, Jia X, Harp CT, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc Natl Acad Sci U S A. 2023 01 17; 120(3):e2207291120.
    View in: PubMed
    Score: 0.150
  18. De Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol. 2022 Jan; 269(1):111-124.
    View in: PubMed
    Score: 0.130
  19. Liu Y, Given KS, Harlow DE, Matschulat AM, Macklin WB, Bennett JL, Owens GP. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun. 2017 03 24; 5(1):25.
    View in: PubMed
    Score: 0.100
  20. Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird NL, Bennett JL, Owens GP. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol. 2015 Dec; 130(6):765-81.
    View in: PubMed
    Score: 0.091
  21. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012 Jul 12; 367(2):115-23.
    View in: PubMed
    Score: 0.072
  22. Brennan KM, Galban-Horcajo F, Rinaldi S, O'Leary CP, Goodyear CS, Kalna G, Arthur A, Elliot C, Barnett S, Linington C, Bennett JL, Owens GP, Willison HJ. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol. 2011 Sep 15; 238(1-2):87-95.
    View in: PubMed
    Score: 0.068
  23. Yu X, Gilden D, Schambers L, Barmina O, Burgoon M, Bennett J, Owens G. Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF. J Neuroimmunol. 2011 Apr; 233(1-2):192-203.
    View in: PubMed
    Score: 0.065
  24. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010 Feb 26; 219(1-2):1-7.
    View in: PubMed
    Score: 0.060
  25. Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES, Burgoon M, Owens GP, Racke MK, Bennett JL, Frohman EM, Monson NL. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol. 2009 Aug 18; 213(1-2):123-30.
    View in: PubMed
    Score: 0.059
  26. Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, Shearer A, Lam C, Yu X, Birlea M, DuPree C, Williamson RA, Hafler DA, Burgoon MP, Gilden D. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009 Jun; 65(6):639-49.
    View in: PubMed
    Score: 0.058
  27. Bennett JL, Haubold K, Ritchie AM, Edwards SJ, Burgoon M, Shearer AJ, Gilden DH, Owens GP. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol. 2008 Aug 13; 199(1-2):126-32.
    View in: PubMed
    Score: 0.055
  28. St?ve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. Pharmacological treatment of early multiple sclerosis. Drugs. 2008; 68(1):73-83.
    View in: PubMed
    Score: 0.053
  29. Winges KM, Gilden DH, Bennett JL, Yu X, Ritchie AM, Owens GP. Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J Neuroimmunol. 2007 Dec; 192(1-2):226-34.
    View in: PubMed
    Score: 0.052
  30. Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol Res. 2006 Apr; 28(3):236-44.
    View in: PubMed
    Score: 0.047
  31. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020 07 14; 95(2):e111-e120.
    View in: PubMed
    Score: 0.031
  32. Raveendra BL, Wu H, Baccala R, Reddy MM, Schilke J, Bennett JL, Theofilopoulos AN, Kodadek T. Discovery of peptoid ligands for anti-aquaporin 4 antibodies. Chem Biol. 2013 Mar 21; 20(3):351-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)